Hans-rudolf Brunner
#113,057
Most Influential Person Now
Hans-rudolf Brunner's AcademicInfluence.com Rankings
Hans-rudolf Brunnerphilosophy Degrees
Philosophy
#4812
World Rank
#7464
Historical Rank
Logic
#2191
World Rank
#3127
Historical Rank

Download Badge
Philosophy
Hans-rudolf Brunner's Degrees
- PhD Medicine University of Zurich
- Doctorate Medicine University of Zurich
Why Is Hans-rudolf Brunner Influential?
(Suggest an Edit or Addition)Hans-rudolf Brunner's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial (2004) (2115)
- Essential hypertension: renin and aldosterone, heart attack and stroke. (1972) (1101)
- Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. (1972) (722)
- Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. (1978) (613)
- Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial (2004) (612)
- Endothelial function in chronic congestive heart failure. (1992) (581)
- Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. (1972) (532)
- Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor (1998) (416)
- Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril (2002) (389)
- Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. (1979) (374)
- Hypertension of Renal Origin: Evidence for Two Different Mechanisms (1971) (349)
- Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. (1998) (342)
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MAN (1977) (330)
- Renal effects of selective cyclooxygenase‐2 inhibition in normotensive salt‐depleted subjects (1999) (329)
- An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. (1974) (324)
- Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. (1991) (291)
- Angiotensin-Sodium Interaction in Blood Pressure Maintenance of Renal Hypertensive and Normotensive Rats (1973) (285)
- Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. (1973) (264)
- Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade (1982) (261)
- Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions (2001) (261)
- Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II (1991) (253)
- Angiotensin Converting Enzyme Inhibition in Patients with Congestive Heart Failure (1978) (252)
- Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. (1973) (242)
- Effects of modulators of the renin—angiotensin—aldosterone system on cough (1994) (238)
- A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists (2013) (231)
- Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. (2000) (224)
- Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. (1995) (214)
- Conduit artery compliance and distensibility are not necessarily reduced in hypertension. (1992) (213)
- Malignant Hypertension Resulting from Deoxycorticosterone Acetate and Salt Excess: ROLE OF RENIN AND SODIUM IN VASCULAR CHANGES (1975) (211)
- The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. (1970) (208)
- Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. (1972) (201)
- Aliskiren: the first renin inhibitor for clinical treatment (2008) (198)
- Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (1992) (191)
- Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. (1973) (191)
- ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421". (1981) (190)
- IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRIL (1979) (172)
- Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. (2000) (171)
- Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout (2001) (160)
- Isolated office hypertension: a prehypertensive state? (1996) (159)
- Three new long‐acting converting‐enzyme inhibitors: Relationship between plasma converting‐enzyme activity and response to angiotensin I (1981) (157)
- Isobaric compliance of the radial artery is increased in patients with essential hypertension (1993) (150)
- The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy (2006) (148)
- Aldosterone Excretion: PHYSIOLOGICAL VARIATIONS IN MAN MEASURED BY RADIOIMMUNOASSAY OR DOUBLE‐ISOTOPE DILUTION (1972) (143)
- Endogenous Angiotensin II Induces Atherosclerotic Plaque Vulnerability and Elicits a Th1 Response in ApoE−/− Mice (2004) (141)
- Reciprocation of renin dependency with sodium volume dependency in renal hypertension. (1975) (125)
- Reciprocal relation between renin dependency and sodium dependency in essential hypertension. (1976) (121)
- Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. (1990) (120)
- Angiotensin II receptor inhibition. A new therapeutic principle. (1996) (120)
- Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. (2001) (120)
- Renin as a risk factor in essential hypertension: more evidence. (1973) (115)
- Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. (2012) (111)
- Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. (2004) (107)
- Proximal Sodium Reabsorption: An Independent Determinant of Blood Pressure Response to Salt (2000) (107)
- Endothelial function in congestive heart failure. (1993) (104)
- Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists (1997) (103)
- Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor? (2003) (103)
- The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension. (1972) (99)
- Monitoring compliance in resistant hypertension: an important step in patient management. (2003) (99)
- The neuropeptide Y Y1 receptor regulates leptin‐mediated control of energy homeostasis and reproductive functions (2002) (98)
- Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing (2002) (94)
- Ambulatory blood pressure recordings. Reproducibility and unpredictability. (1984) (93)
- A device for subjecting vascular endothelial cells to both fluid shear stress and circumferential cyclic stretch (1994) (89)
- VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk (2003) (88)
- The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. (1997) (87)
- Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial (2001) (86)
- Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. (2000) (85)
- In Vitro and in Vivo Characterization of the Activity of Telmisartan: An Insurmountable Angiotensin II Receptor Antagonist (2002) (83)
- The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. (1975) (83)
- Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. (1981) (79)
- Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil Assessed by 24-Hour Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension (2003) (78)
- Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. (2002) (74)
- The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview (2002) (74)
- Renin Subgroups in Essential Hypertension: FURTHER ANALYSIS OF THEIR PATHOPHYSIOLOGICAL AND EPIDEMIOLOGICAL CHARACTERISTICS (1973) (73)
- INNAPPROPRIATE RENIN SECRETION UNMASKED BY CAPTOPRIL (SQ 14 225) IN HYPERTENSION OF CHRONIC RENAL FAILURE (1978) (73)
- NPY regulates catecholamine secretion from human adrenal chromaffin cells. (2001) (72)
- Clinical Use of an Orally Acting Converting Enzyme Inhibitor: Captopril (1980) (72)
- Spontaneous diameter oscillations of the radial artery in humans. (1993) (71)
- Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients (1998) (70)
- ARE SOME HYPERTENSIVE PATIENTS OVERTREATED? A Prospective Study of Ambulatory Blood Pressure Recording (1987) (70)
- Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice (2003) (70)
- Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma. (2001) (69)
- Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. (2001) (68)
- Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade. (1978) (68)
- Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. (1977) (67)
- Confocal microscopy to analyze cytosolic and nuclear calcium in cultured vascular cells. (1994) (66)
- Calcineurin Blockade Prevents Cardiac Mitogen-activated Protein Kinase Activation and Hypertrophy in Renovascular Hypertension* (2000) (65)
- Flow-mediated arterial dilation is abnormal in congestive heart failure (1993) (64)
- Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice (2001) (63)
- Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension (1995) (62)
- Production and characterization of four anti-neuropeptide Y monoclonal antibodies. (1992) (61)
- Aortic connexin43 is decreased during hypertension induced by inhibition of nitric oxide synthase. (1999) (61)
- Evaluation of Arterial Compliance‐Pressure Curves Effect of Antihypertensive Drugs (1991) (60)
- Unidirectional and oscillatory shear stress differentially modulate NOS III gene expression. (2000) (60)
- Postischemic blood flow response in hypercholesterolemic patients. (1995) (59)
- Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? (1977) (59)
- Tissue Factor Activity Is Upregulated in Human Endothelial Cells Exposed to Oscillatory Shear Stress (2002) (58)
- Why Objective Monitoring of Compliance is Important in the Management of Hypertension. (2000) (58)
- Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. (2016) (57)
- Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. (2001) (56)
- ACE inhibitors in renal disease. (1992) (56)
- Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations. (1997) (56)
- Plasma aldosterone-renin interrelationships in various forms of essential hypertension. Studies using a rapid assay of plasma aldosterone. (1973) (56)
- Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. (2000) (55)
- Fatal pancytopenia associated with the use of captopril. (1981) (54)
- Hemodynamic and Humoral Effects of the New Renin Inhibitor Enalkiren in Normal Humans (1989) (52)
- Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats. (1994) (52)
- VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. (2004) (52)
- Dose-response relationships following oral administration of DuP 753 to normal humans. (1991) (52)
- Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter. (2004) (51)
- Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation. (1974) (50)
- Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects (1986) (50)
- Practical solutions to the challenges of uncontrolled hypertension: a white paper (2008) (49)
- Effect of magnesium deficiency on blood pressure and mechanical properties of rat carotid artery. (1999) (49)
- Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects (1995) (47)
- Pharmacokinetics and Pharmacodynamics of Pentopril, a New Angiotensin‐Converting‐Enzyme Inhibitor in Humans (1986) (47)
- Sodium-induced elevation of blood pressure in the anephric state. (1980) (47)
- Renal hemodynamic and tubular responses to salt in women using oral contraceptives. (2003) (46)
- Dynamic non‐invasive measurements of arterial diameter and wall thickness (1992) (46)
- Contributions of vascular tone and structure to elastic properties of a medium-sized artery. (1996) (45)
- Angiotensin blockade for hypertension: a promise fulfilled (2002) (45)
- Diabetes mellitus and vascular lesions. (1998) (44)
- Simultaneous ipsilateral and contralateral measurements of vasomotion in conduit arteries of human upper limbs. (1995) (43)
- Hemodynamic and Biochemical Consequences of Renin Inhibition by Infusion of CGP 38560A in Normal Volunteers (1989) (42)
- Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals (2011) (41)
- Differential nitric oxide synthase activity in human platelets during normal pregnancy and pre-eclampsia. (1995) (41)
- Effect of the Renin Response During Renin Inhibition: Oral Ro 42–5892 in Normal Humans (1991) (40)
- Salt‐ And Angiotensin Ii‐Dependent Variations In Amiloride‐Sensitive Rectal Potential Difference In Mice (2000) (40)
- Blood pressure and endocrine effects of single doses of CS‐866, a novel angiotensin II antagonist, in salt‐restricted hypertensive patients (1997) (38)
- Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. (2001) (38)
- Magnesium supplementation and deoxycorticosterone acetate--salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1. (2002) (37)
- Ambulatory blood pressure recording to identify hypertensive patients who truly need therapy. (1984) (37)
- Norepinephrine and Renin Activity in Chronic Renal Failure: Evidence for Interacting Roles in Hemodialysis Hypertension (1981) (37)
- Angiotensin Converting Enzyme Inhibition: Discrepancy Between Antihypertensive Effect and Suppression of Enzyme Activity (1989) (37)
- Clinical experience with angiotensin II receptor antagonists. (1992) (37)
- Converting enzyme inhibition in hypertensive emergencies. (1979) (36)
- Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. (1994) (36)
- The Opposing Effects of Chronic Angiotensin‐Converting Enzyme Blockade by Captopril on the Responses to Exogenous Angiotensin II and Vasopressin vs. Norepinephrine in Rats (1981) (36)
- Cardiac hypertrophy depends upon sleep blood pressure: a study in rats (2000) (36)
- Time course changes of the mechanical properties of the carotid artery in renal hypertensive rats. (1997) (36)
- Endotheliai function of the mesenteric arteriole and mechanical behaviour of the carotid artery in rats with insulin resistance and hypercholesterolaemia (1995) (36)
- Renal segmental tubular response to salt during the normal menstrual cycle. (2002) (35)
- Angiotensin II blockade in normal man: interaction of renin and sodium in maintaining blood pressure. (1977) (35)
- Intraluminal pressure modulates the magnitude and the frequency of induced vasomotion in rat arteries. (1995) (34)
- The return of increased blood pressure after discontinuation of antihypertensive treatment is associated with an impaired post-ischemic skin blood flow response (2001) (34)
- Main objectives and new aspects of combination treatment of hypertension (1995) (33)
- Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1‐receptor antagonist (2001) (33)
- Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading (2000) (33)
- Converting Enzyme Inhibition During Chronic Angiotensin II Infusion in Rats: Evidence Against a Nonangiotensin Mechanism (1981) (33)
- Prevention of renal hypertension in the rat by neuropeptide Y. (1990) (32)
- Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. (1978) (32)
- Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy (2012) (32)
- Endothelial dysfunction in chronic heart failure. Experimental and clinical studies. (1994) (31)
- Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats. (1978) (31)
- Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. (1982) (31)
- Clinical efficacy of olmesartan medoxomil. (2003) (31)
- Angiotensin II Receptor Blockade in Normotensive Subjects A Direct Comparison of Three AT 1 Receptor Antagonists (1999) (31)
- Blood pressure response to antihypertensive therapy: ambulatory versus office blood pressure readings. (1985) (31)
- Renal and neurohormonal responses to increasing levels of lower body negative pressure in men. (2001) (30)
- Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men (2002) (30)
- Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An Update (1981) (30)
- NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-α and IFN-γ in HUVEC (2003) (30)
- Clinical efficacy and tolerability of olmesartan. (2004) (29)
- Renin and aldosterone and the pathogenesis of hypertensive vascular damage. (1974) (29)
- Effects of tyrosine infusion in normotensive and hypertensive rats. (1980) (29)
- Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy (2013) (29)
- Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension (1992) (29)
- Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor (2003) (29)
- Dibasic cleavage site is required for sorting to the regulated secretory pathway for both pro‐ and neuropeptide Y (2002) (29)
- Is the renin system necessary? (1980) (29)
- The VALUE Trial (2005) (28)
- Sustained 24‐hour blockade of the renin‐angiotensin system: A high dose of a long‐acting blocker is as effective as a lower dose combined with an angiotensin‐converting enzyme inhibitor (2005) (28)
- Olmesartan medoxomil: current status of its use in monotherapy (2006) (28)
- Vasopressin in Salt‐Induced Hypertension of Experimental Renal Insufficiency (1982) (28)
- Neuropeptide Y expression, localization and cellular transducing effects in HUVEC (2005) (28)
- The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension. (1975) (28)
- Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. (1992) (28)
- Dietary magnesium intake can affect mechanical properties of rat carotid artery (2000) (27)
- Age‐related changes of the mechanical properties of the carotid artery in spontaneously hypertensive rats (1997) (27)
- Angiotensin II measurement with high‐affinity monoclonal antibodies (1988) (27)
- Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. (2003) (27)
- Rapid Site-Directed Mutagenesis Using Two-PCR-Generated DNA Fragments Reproducing the Plasmid Template (2003) (26)
- Response of plasma vasopressin to changes in extracellular volume and/or plasma osmolality in patients on maintenance hemodialysis. (1985) (26)
- Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers (2002) (25)
- Compensatory up-regulation of angiotensin II subtype 1 receptors in alpha ENaC knockout heterozygous mice. (2001) (25)
- Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. (1997) (25)
- Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. (1980) (24)
- Noninvasive Blood Pressure Monitoring at the Finger for Studying Short Lasting Pressor Responses in Man (1990) (24)
- RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers. (1981) (24)
- Antagonizing and Measurement: Approaches to Understanding of Hemodynamic Effects of Kinins (1992) (23)
- Differences in the mechanical properties of the rat carotid artery in vivo, in situ, and in vitro. (1998) (23)
- Suppression of Renin and Aldosterone by Clonidine. (1971) (23)
- Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay. (1999) (22)
- Neuropeptide Y Y2 receptor signalling mechanisms in the human glioblastoma cell line LN319 (2001) (22)
- Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. (1993) (21)
- Increased response of brachial artery diameter to norepinephrine in hypertensive patients. (1988) (21)
- Introduction to arterial compliance and function. (1992) (21)
- Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. (1978) (21)
- In-vitro response of plasma angiotensin converting enzyme to precursors and active forms of converting enzyme inhibitors (1984) (21)
- Role of Reactive Hyperreninemia in Blood Pressure Changes Induced by Sodium Depletion in Patients with Refractory Hypertension (1981) (21)
- A Comparative Study of the Effects of Oxprenolol Versus Propranolol in Essential Hypertension (1979) (21)
- Evidence for a sodium-induced activation of central neurogenic mechanisms in one-kidney, one-clip renal hypertensive rats. (1982) (20)
- Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers (1991) (20)
- Role of vasoconstrictor systems in experimental glucocorticoid-hypertension in rats. (1983) (20)
- Renal and hemodynamic effects of atrial natriuretic peptide in patients with cirrhosis. (1990) (20)
- Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. (2000) (20)
- Non‐invasive method for the assessment of non‐linear elastic properties and stress of forearm arteries in vivo (1992) (19)
- Value of Different Clinical and Biochemical Correlates to Assess Angiotensin Converting Enzyme Inhibition (1994) (18)
- ET-1 and NOS III gene expression regulation by plaque-free and plaque-prone hemodynamic conditions. (2003) (18)
- Need for beta-blockade in hypertension reduced with long-term minoxidil. (1978) (17)
- Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. (1982) (17)
- Comparison of the Angiotensin II Antagonist UP269–6 with the Angiotensin Converting Enzyme Inhibitor Enalapril in Normotensive Volunteers Challenged with Angiotensin I (1995) (17)
- Isolated perfused mesenteric arteries of hypertensive and normotensive rats; response to norepinephrine, lysine vasopressin and angiotensin II. (1985) (16)
- Endothelin inhibition as a biologic target for treating hypertension. (1998) (16)
- High level expression of human neuropeptide Y receptors in mammalian cells infected with a recombinant vaccinia virus (1993) (16)
- Vascular Damage in Hypertension (1975) (16)
- Effect of Nadolol in Treatment of Hypertension (1979) (16)
- Heterogeneous vascular response to vasopressin: radial artery versus forearm blood flow. (1997) (15)
- NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. (2003) (15)
- Accuracy, reproducibility and usefulness of ambulatory blood pressure recording obtained with the Remler system (1984) (14)
- Salt-induced hypertension in chronic renal failure: evidence for a neurogenic mechanism. (1983) (14)
- Clinical implications of renin in the hypertensive patient. (1975) (14)
- Neuropeptide Y Prevents the Blood Pressure Fall Induced by Endotoxin in Conscious Rats With Adrenal Medullectomy (1988) (14)
- Arterial dilatory reserve in congestive heart failure (1992) (14)
- Non‐invasive measurement of internal diameter of peripheral arteries during the cardiac cycle (1988) (14)
- Antihypertensive Efficacy of Ketanserin Alone or in Combination with a β‐Blocker or a Diuretic: The Swiss Ketanserin Study (1987) (13)
- INHIBITORY EFFECT OF NEUROPEPTIDE Y ON STIMULATED RENIN SECRETION OF AWAKE RATS (1992) (13)
- Is nurse-measured blood pressure a valid substitute for ambulatory blood pressure monitoring? (2000) (13)
- Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881. (1974) (13)
- Mode of action of antihypertensive drugs (1966) (13)
- Interactions between NPY and its receptor: assessment using anti-NPY antibodies (1994) (13)
- Individualization of antihypertensive therapy. (1988) (13)
- Effect of Ganglion Blockade with Pentolinium on Circulating Neuropeptide Y Levels in Conscious Rats (1988) (13)
- Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension. (1979) (13)
- Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril. (1982) (12)
- The Renin-Angiotensin-Aldosterone System in Congestive Heart Failure (1983) (12)
- Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension. (1981) (12)
- Transient inhibition of angiotensinogen production in transgenic mice bearing an antisense angiotensinogen gene. (1995) (11)
- Physiologic studies with saralasin in animals. (1979) (11)
- Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist (1995) (11)
- Neuropeptide Y ( NPY ) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y 5 receptors (2000) (11)
- [Local pulse pressure and regression of arterial wall hypertrophy during antihypertensive treatment. CELIMENE study. The Celiprolol Intima-Media Enalapril Efficacy study]. (2000) (10)
- Is hyperuricaemia a predictor of cardiovascular risk (1999) (10)
- Renal haemodynamic and protective effects of calcium antagonists in hypertension. (1995) (10)
- Pseudo-Primary Aldosteronism, a Variant of Low Renin, Essential Hypertension? (1972) (10)
- Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance. (1976) (10)
- Elastic behaviour of the carotid artery in intact spontaneously hypertensive rats. (1993) (10)
- Remodelling of conduit arteries in hypertension: special emphasis on the mechanical and metabolic consequences of vascular hypertrophy. (1997) (10)
- Differential Secretion of Catecholamine and Neuropeptide Y in Response to KCl from Mice Chromaffin Cells (2002) (10)
- Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly (1989) (10)
- Captopril in the treatment of hypertension. (1981) (10)
- Angiotensin converting enzyme inhibition and renin inhibition (1989) (9)
- Influence of sodium diet and deoxycorticosterone on the response to norepinephrine, lysine-vasopressin and angiotensin II of isolated perfused rat mesenteric arteries. (1983) (9)
- Regionalized self-care hemodialysis. A solution to the increasing cost. (1983) (9)
- Does protein binding modulate the effect of angiotensin II receptor antagonists? (2001) (8)
- Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress. (2004) (8)
- Vasopressin dilates the rat carotid artery by stimulating V1 receptors. (1998) (8)
- Clinical hypertension and hypotension (1982) (8)
- Effect of eight-day converting enzyme inhibition on ambulatory blood pressure recordings in normotensive volunteers. (1987) (8)
- Aortic Connexin 43 Is Decreased During Hypertension Induced by Inhibition of Nitric Oxide Synthase (1999) (8)
- DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan (1997) (8)
- [Autoregulation of the papillary vessels and their behavior as affected by halothane]. (1988) (8)
- Converting enzyme inhibition during chronic angiotensin II infusion in rats: evidence against a non-angiotensin mechanism. (1980) (8)
- Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats (1995) (7)
- Changes in treatment during and after hospitalization in patients taking drugs for cardiovascular diseases (1996) (7)
- Vascular sympathetic nerve function in congestive heart failure. (1988) (7)
- Effect of mental stress on the tone of a medium‐sized muscular artery (1992) (7)
- Effects of intranasal administration of synthetic (4-28)human atrial natriuretic peptide to normal volunteers. (1989) (6)
- Volume expansion enhances plasma endothelin-1. (2003) (6)
- Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. (2000) (6)
- The renin-angiotensin system in hypertension: an update. (1990) (6)
- The renin-angiotensin system and the heart: beyond 2000 (1996) (6)
- [Prognostic value of the renin-angiotensin system in response to salt restriction and prognosis of alcoholic ascitic cirrhosis]. (1986) (6)
- RATIONAL USE OF CAPTOPRIL (1979) (6)
- Coronary and peripheral artery remodeling in patients undergoing PTCA: An intracoronary and transcutaneous ultrasound study (1999) (6)
- [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia]. (1990) (6)
- Hemodynamic Effects of a Kinin Antagonist (1990) (6)
- Ambulatory Blood Pressure Recording (1994) (6)
- Vasopressin induces opposite changes in blood flow in the skin and the muscular circulation. (1998) (5)
- Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’: EXPERIENCE WITH ANGIOTENSIN II ANTAGONISTS IN HYPERTENSIVE PATIENTS (1996) (5)
- Treatment of Hypertension with ACE Inhibitors as First Step: Pharmacologic and Clinical Considerations (1987) (5)
- Evolution and hypertension: is the Renin system necessary? (2007) (5)
- Objective monitoring of drug compliance: an important step in the management of hypertension resistant to drug therapy. (1999) (5)
- Clinical experience with angiotensin II receptor antagonists. (1993) (5)
- Valsartan in the treatment of hypertension (2005) (5)
- Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system. (1979) (5)
- The antihypertensive effect of beta-blockers. (1977) (4)
- [Increased vascular sensitivity to nitroglycerin in patients with hypercholesterolemia and peripheral endothelial dysfunction]. (2008) (4)
- Round Table: What blood pressure to measure? (1991) (4)
- Vasopressin Blood Pressure Dependency after α-Adrenoceptor Blockade in Normotensive and Mineralocorticoid-Salt Hypertensive Rats (1982) (4)
- Immersion and venous occlusion plethysmography in patients with idiopathic orthostatic hypotension. (1981) (4)
- Validation of in-vitro data by in-vivo evidence: the example of angiotensin (1-7). (2006) (4)
- Salt Subtraction in Patients on Maintenance Hemodialysis (1985) (4)
- Renin and Aldosterone in the Etiology and Prognosis of Essential Hypertension: Their Relation to Vascular Complications (1972) (4)
- THE VALSARTAN ANTIHYPERTENSIVE LONGTERM USE EVALUATION (VALUE) TRIAL: FINAL PATIENTS DEMOGRAPHICS (2000) (4)
- TACHYCARDIA IS A STRONG PREDICTOR OF CARDIOVASCULAR EVENTS IN THE VALUE TRIAL: 6A.04 (2010) (4)
- Interaction of the Sympathetic Nervous System with Vasopressin and Renin in the Maintenance of Blood Pressure in Rats (1982) (4)
- Clinical Utility of Ambulatory Blood Pressure Monitoring in the Evaluation of Patients with Borderline Hypertension (1994) (4)
- The role of hormones in congestive heart failure: new frontiers in therapy? (1982) (3)
- Angiotensin II blockade in congestive heart failure. (1978) (3)
- Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin. (1989) (3)
- B027 Assessment of angiotensin II receptor blockade in humans using an in vitro binding assay: Comparison with the in vivo approach (1998) (3)
- Arterial compliance and distensibility in spontaneously hypertensive rats (1992) (3)
- [Angiotensin II inhibitors for the diagnosis and treatment of hypertension]. (1976) (3)
- Saralasin in human hypertension: the early experience. (1979) (3)
- Redistribution of regional blood flow after administration of saralasin in salt-depleted dogs. (1978) (3)
- Pre- and Postsynaptic Effects of SKF64139, a Phenylethanolamine N‐Methyltransferase Inhibitor, in Conscious Normotensive Rats (1982) (3)
- Effect of indomethacin and propranolol on the blood pressure and renin response to atriopeptin III in conscious rats (1987) (3)
- Effect of Neuropeptide Y on Stimulated Renin Secretion a (1990) (3)
- The Renin System in Hypertension (1987) (3)
- Position Paper: Angiotensin-Converting Enzyme Blockade as a Therapeutic Modality (1981) (2)
- PP.02.34: SAFETY OF LONG-TERM ENRICHED POTASSIUM SALT CONSUMPTION AND EFFECT ON BLOOD PRESSURE IN CHINESE (2015) (2)
- [Inhibition of plasmatic renin activity by potassium]. (1967) (2)
- Position of beta blockers in antihypertensive therapy. (1986) (2)
- [Prevention of myocardial infarct?]. (1978) (2)
- [Hyperreactivity of the humeral artery to noradrenaline in essential hypertension patients]. (1987) (2)
- Letter: Renin profiling in hypertension. (1976) (2)
- [Non invasive measurement of arterial compliance]. (1991) (2)
- Salt subtraction in patients on maintenance hemodialysis. Efficacy and limitations. (1985) (2)
- [Changes in medications acting on the cardiovascular system during hospitalization]. (2000) (2)
- Angiotensin converting enzyme inhibition: a new therapeutic modality. (1981) (2)
- Introduction: Position of beta blockers in antihypertensive therapy (1986) (2)
- Hypertension, Vasopressors, and Susceptibility to Vascular Injury: Experimental and Clinical Studies (1981) (2)
- Initial evaluation of the angiotensin converting enzyme inhibitor CGS 13945 in hypertensive patients (1985) (2)
- Determination of renin-dependency and sodium-dependency in the three renin sub-groups of essential hypertension. (1976) (2)
- Role of vasoactive peptides in blood pressure control. (1993) (2)
- Clinical Application of Treatment with Angiotensin Receptor Antagonists (1994) (2)
- [Physiopathology of left ventricular hypertrophy]. (1995) (2)
- Position Paper: Vasoconstriction and Volume Factors in Renovascular Hypertension (1981) (2)
- [Effect of atrial natriuretic factor on the hematocrit of patients in chronic hemodialysis]. (1987) (2)
- Captopril: an oral angiotension converting enzyme inhibitor active in man. (1980) (2)
- Postpropranolol vasodilation in adrenalectomized glucocorticoid hypertensive rats. (1987) (1)
- OS 03-06 EFFECT OF LONG-TERM ENRICHED POTASSIUM SALT CONSUMPTION ON ALL CAUSES MORTALITY IN CHINESE LIVING IN NURSING HOUSES—A PRELIMINARY ANALYSIS (2016) (1)
- INVESTIGATING THE CRITICAL SITUATION IN HYPERTENSION MANAGEMENT: DISPARITIES BETWEEN THE PERCEPTION AND REALITY OF THE BURDEN OF ‘CHALLENGING PATIENTS’ (SHARE SURVEY): PP.26.55 (2010) (1)
- [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy]. (1989) (1)
- Lack of a Role of the Parasympathetic Nervous System in the Haemodynamic Response of Normotensive Rats to Atriopeptin III (1986) (1)
- Prevention of vascular remodelling in cardiovascular disease. (1995) (1)
- O-36: The orally active renin inhibitor SPP100 blocks the renin-angiotensin system in humans equally well as enalapril* (2001) (1)
- The Position of β-Blockers in Antihypertensive Therapy (1979) (1)
- P-453 *Program Revision (see p. 267A): Gender specific characteristics of 15,288 hypertensive patients at high coronary risk. The value trial (2001) (1)
- [Cirrhotic ascites and the renin-angiotensin system]. (1980) (1)
- A symposium : the role of angiotensin II receptor antagonists in the management of hypertension (1999) (1)
- 3. Effects of neuropeptide Y on renal hemodynamics and plasma renin activity of conscious normotensive rats (1991) (1)
- Antihypertensive Agents: Mechanisms of Drug Action (2003) (1)
- Pathophysiological concepts of renovascular hypertension. (1976) (1)
- [Renin and sodium in blood pressure regulation]. (1974) (1)
- Chapter 81 – Angiotensin II Receptor Blockers (2007) (1)
- The value trial: patients demographics and progress report. (1999) (1)
- INVESTIGATING THE CRITICAL SITUATION IN HYPERTENSION MANAGEMENT: IS PHYSICIAN INERTIA PUTTING PATIENTS AT INCREASED CARDIOVASCULAR RISK? (SHARE SURVEY): 4B.06 (2010) (1)
- 235 Influence of sodium intake on the renin-angiotensin system of rats with hypertension caused by chronic inhibition of nitric oxide synthesis (1993) (1)
- O-28: Molecular basis for the insurmountable AT-1 receptor antagonism of telmisartan (2001) (1)
- Discontinuation of chronic haemodialysis after control of arterial hypertension; long term follow-up. (1983) (1)
- Simvastatin in the treatment of type II hyperlipoproteinemia in the elderly : a two-year experience (1991) (1)
- Renal endothelin receptor type B upregulation in rats with low or high renin hypertension (2004) (1)
- Early experience with angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors. (2001) (1)
- Coronary and peripheral artery remodeling in patients undergoing PTCA: An intracoronary and transcutaneous ultrasound study. (1999) (1)
- A8338 Effects of long-term enriched potassium salt consumption on premature death in Chinese living in nursing houses—preliminary analysis (2018) (1)
- Neither hydralazine nor captopril significantly shifts carotid artery distensibility-pressure curves determined in intact spontaneously hypertensive rats. (1991) (1)
- INVESTIGATING THE CRITICAL SITUATION IN HYPERTENSION MANAGEMENT: PHYSICIAN PERCEPTION AND USE OF THE ESH–ESC TREATMENT GUIDELINES (SHARE SURVEY): PP.20.306 (2010) (1)
- [Treatment of refractory ascites by means of the LeVeen shunt]. (1981) (1)
- Aldosterone Excretion PHYSIOLOGICAL VARIATIONS IN MAN (2005) (1)
- Enhanced Urinary Kallikrein Excretion in Response to a Moderate Sodium Load in Genetically Hypertensive Rats (1988) (1)
- DARK URINE AFTER EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY (1987) (1)
- 108. Drug concentration-response relationships in normal volunteers after oral administration of DuP 753, an angiotensin II antagonist (1991) (1)
- Under pressure: future prospects in hypertension management (2008) (0)
- [Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. (1978) (0)
- Effect of ANF on Urinary Kallikrein in Normal Man (1986) (0)
- [Initial experiences with peritoneo-venous shunting by means of the Le Veen pressure-sensitive valve in the treatment of refractory ascites]. (1980) (0)
- Introduction: moving towards the ideal angiotensin II receptor antagonist—building a consensus (1999) (0)
- Characteristics of Renin Subgroups of Patients with Essential Hypertension. (1973) (0)
- Preface: Swiss Hypertension Workshop on Vasopressin. (1986) (0)
- [The ambulatory measure of tension profile with the Remler Portable Device (author's transl)]. (1981) (0)
- Is Antihypertensive Therapy Expected to be Different in Postmenopausal Women (1994) (0)
- PS-C37-5: NEW THERAPEUTIC PERSPECTIVES FOR BLOOD PRESSURE CONTROL: DEXFADROSTAT PHOSPHATE, A NOVEL ALDOSTERONE SYNTHASE INHIBITOR, IN PATIENTS WITH PRIMARY ALDOSTERONISM (2023) (0)
- OR-53: Plasma immunoreactive endothelin-1 levels in hypertensive rats and human subjects (2003) (0)
- B017: The valsartan antihypertensive longterm use evaluation (VALUE) trial: Final patients demographics (2000) (0)
- Femoral atherosclerosis has a higher predictive value than carotid for detection of coronary heart disease (2000) (0)
- Expression of concern (2018) (0)
- HEART-FAILURE - DISCUSSION (1986) (0)
- Transgenic mice with disrupted NPY Y1 receptor genes (1997) (0)
- Comparison of the angiotensin II receptor blockade induced by tasosartan and its active metabolite enoltasosartan in healthy subjects. (1999) (0)
- Determination of cardiac contractility in mice Comparison of two catheters and evaluation of the role of anesthesia (2002) (0)
- The use of angiotensin II antagonists in combination treatment of hypertension (2006) (0)
- ANTIHYPERTENSIVE ACTION OF P-ADRENOCEPTOR BLOCKADE AND THE RENIN-ANGIOTENSIN SYSTEM (2006) (0)
- MULTIFACTOR REGULATION OF ALDOSTERONE (1965) (0)
- Round table discussion: what blood pressure to measure? (1991) (0)
- Angiotensin inhibitors for hypertension. (1980) (0)
- [Causes favoring urinary infections and their treatment]. (1977) (0)
- Individual variability to antihypertensive treatment and in organ complications (1995) (0)
- Modulation of the tissue factor expression by various hemodynamic forces (2000) (0)
- CYP11B2 Inhibitor Dexfadrostat Phosphate Suppresses the Aldosterone-to-Renin Ratio, an Indicator of Sodium Retention, in Healthy Volunteers. (2023) (0)
- 27 Cross-talk between intracellular calcium signalling pathways activated by neuropeptide Y and angiotensin II in human erythroleukaemia cells (1993) (0)
- 21 Biotinylation and fluorescein labelling of angiotensin II (1991) (0)
- Shorter PFA-100-closure times in laparoscopic versus conventional hysterectomy are not caused by increased vasopressin levels. (2006) (0)
- Human angiotensin I competes with two non‐thiol converting enzyme inhibitors (CGS 13934 & MK‐422) to inhibit the angiotensin‐converting enzyme activity of human plasma (1984) (0)
- Measurement of activity of angiotensin converting enzyme in biological sample (1992) (0)
- Rational Prescribing in Suboptimal Compliance (2002) (0)
- The position of beta-blockers in antihypertensive therapy. Comparison with other antihypertensive agents. (1979) (0)
- An easy approach to cardiovascular protection (1997) (0)
- Ambulatory blood pressure recordings. Reproducibility and unpredictability. (1984) (0)
- Systemtic and reg.ional hemodynamic effects of perindopril in exp.erimentaI heart fa.ilure (1993) (0)
- The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension (1980) (0)
- Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension. (1981) (0)
- Hormonal, global, andregional haemodynamic responses toavascular antagonist ofvasopressin in patients withcongestive heart failure withand without hyponatraemia (1986) (0)
- CLINICAL AND EXPERIMENTAL ASPECTS OF THE ANGIOTENSIN CONVERTING ENZYME IN BLOOD PRESSURE REGULATION (1983) (0)
- Diabetic nephropathy in normotensive patients. Discussion (1990) (0)
- 47 The value of different humoral correlates in assessing the blockade of angiotensin II generation by the angiotensin converting enzyme inhibitor CS 622 (1993) (0)
- Clinical trials of antihypertensive drugs (2004) (0)
- A8Hypertension induced by inhibition of nitric oxide synthase: effects on renin and kinins (1995) (0)
- [Arterial hypertension in chronic renal insufficiency]. (1978) (0)
- EFFECTS OF SINGLE OR MULTIPLE DRUG THERAPIES ON CARDIOVASCULAR OUTCOMES IN HYPERTENSION: ANALYSIS OF DATA FROM THE VALUE TRIAL: 6C.04 (2011) (0)
- [28] - Cytosolic and Nuclear Calcium Imaging by Confocal Microscopy (1996) (0)
- Expression of concern (2018) (0)
- Congestive heart failure in normotensive man Haemodynanics , renin , and angiotensin II blockade GUSTAVE (0)
- [Noninvasive assessment of morphology and function of the great vessels]. (1995) (0)
- Clinical application of orally active angiotensin converting enzyme inhibitors. (1983) (0)
- [Usefulness of ambulatory registration of arterial pressure in therapeutic trials of antihypertensive agents]. (1985) (0)
- OS 03-06 EFFECT OF LONG-TERM ENRICHED POTASSIUM SALT CONSUMPTION ON ALL CAUSES MORTALITY IN CHINESE LIVING IN NURSING HOUSES-A PRELIMINARY ANALYSIS. (2016) (0)
- Angiotensin II‐induced cardiac hypertrophy is associated with associated with different mitogen‐activated protein kinase activation in normotensive and hypertensive mice (2000) (0)
- Urinary aldosterone and sodium reabsorption in the distal nephron correlate with the activity of amiloride-sensitive sodium channels. (1999) (0)
- [Interrelations between potassium, renin and aldosterone]. (1966) (0)
- [Blood pressure recording in outpatient service: experience with the Sandoz Pressure System]. (1993) (0)
- FIBROBLAST GROWTH FACTOR-2 MEDIATES ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY IN HYPERTENSIVE MICE THROUGH MAPK ACTIVATION: 5B.8 (2000) (0)
- [Is prevention of chronic renal insufficiency possible?]. (1976) (0)
- Mediators in Septic Shock: The Renin-Angiotensin System (2019) (0)
- P-225: Predictors of one year blood pressure control and treatment resistance in the value trial (2002) (0)
- Comparative Cardiovascular Effects of Drugs Used for Hypertension (2012) (0)
- 179 Active dilation of the carotid artery induced by vasopressin in the intact rat (1993) (0)
- J020: Endogenous lithium clearance to assess the salt-dependent changes in renal sodium handling: Effect of acute water loading (1998) (0)
- Pathophysiology of proteinuria in diabetic glomerular disease. Discussion (1990) (0)
- P-537: Pioglitazone blunts the blood pressure response to angiotensin II in insulin-resistant zucker rats (2003) (0)
- Transportable device for intermittent compression to support a return transport of body fluid towards the heart, and using this apparatus, (1998) (0)
- Measurement and analysis of arterial diameter-pressure curves: A novel method based on ultrasonic and photoplethysmographic techniques (1989) (0)
- 46 Inhibition of pressor responses to exogenous angiotensin II during an 8-day oral treatment of normal subjects with TCV116, an angiotensin II antagonist (1993) (0)
- [Renin and sodium and the formation of vascular lesions in hypertension]. (1974) (0)
- Calcium Antagonists and Renin-Angiotensin Inhibitors: New Antihypertensive Treatment Assets (1985) (0)
- Introduction to the use of ambulatory blood pressure in therapeutic evaluations (1991) (0)
- Characterization of endohelial function in patients with chronic heart failure (1991) (0)
- [Definition and measurement values of acute respiratory insufficiency: ventilation, gas exchange and respiratory mechanics]. (1991) (0)
- Role of Neuropeptide y in Endotoxemia (2019) (0)
- Traitement chronique de l'hypertension arterielle par un inhibiteur de l'enzyme de conversion de l'angiotensine. [Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme] (1978) (0)
- D012 Valsartan antihypertensive longterm use evaluation (the value study) (1998) (0)
- Magnesium and mechanical properties of rat carotid artery. (2001) (0)
- 24H BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM BY ONCE DAILY DOSES OF OLMESARTAN MEDOXOMIL GIVEN ALONE OR IN ASSOCIATION WITH AN ACE-INHIBITOR TO HEALTHY MEN: P2.347 (2004) (0)
- [Discontinuation of chronic hemodialysis due to improved kidney function caused by the control of arterial hypertension]. (1979) (0)
- Evaluation of the interaction of tasosartan and enoltasosartan with plasma proteins using an angiotensin II receptor binding assay. (1999) (0)
- P-620: Pioglitazone stimulates renin and favors sodium retention and weight gain in healthy subjects (2003) (0)
- Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade? (1995) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hans-rudolf Brunner?
Hans-rudolf Brunner is affiliated with the following schools: